Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Apretude 30 mg film-coated tablets {equilateral_black_triangle}

Active Ingredient:
cabotegravir
Company:  
ViiV Healthcare UK Ltd See contact details
ATC code: 
J05AJ04
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Live Chat HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Apretude Guide for prescriber

{healthcare_pro_orange} For Healthcare Professionals

The educational guides for prescribers and individuals at risk will help to increase awareness and provide guidance to mitigate the risks of HIV-1 acquisition and the development of resistance, in line with the UK SmPC.

{pdf_link}

Apretude Guides for individuals at risk

{healthcare_pro_orange} For Healthcare Professionals

The educational guides for prescribers and individuals at risk will help to increase awareness and provide guidance to mitigate the risks of HIV-1 acquisition and the development of resistance, in line with the UK SmPC.

{pdf_link}

Apretude Prescriber Checklist

{healthcare_pro_orange} For Healthcare Professionals

The checklist is intended to facilitate consultation between the prescriber and individual during Cabotegravir for PrEP injection visits, to ensure a consistent approach to evaluating, counselling and follow up of individuals to mitigate the risks of HIV-1 acquisition and development of resistance.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

ViiV Healthcare UK Ltd
Company image
Address
79 New Oxford Street, London, WC1A 1DG, UK
Telephone
+44 (0)800 221 441